1-16 of 16
Marek Ancukiewicz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC)

Yves Boucher, John D. Martin, Sara M. Tolaney, Giogio Seano, Shom Goel, Marek Ancukiewicz, Steven J. Isakoff, Eric P. Winer, Ian E. Krop, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-76.
https://doi.org/10.1158/1538-7445.AM2013-LB-76
Published: 15 April 2013
View article titled, Abstract LB-76: Tissue biomarkers and interstitial fluid pressure in a phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC)
Journal Articles

Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo

Dan G. Duda, Sara M. Tolaney, Marek Ancukiewicz, Eric P. Winer, Ian E. Krop, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-81.
https://doi.org/10.1158/1538-7445.AM2013-LB-81
Published: 15 April 2013
View article titled, Abstract LB-81: A study of circulating biomarkers of angiogenesis and inflammation in ER+ breast cancer (BC) versus triple-negative breast cancer (TNBC) patients enrolled in a phase II study of preoperative treatment with 1 cycle of Bevacizumab followed by standard chemo
Journal Articles

Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion

A. Gregory Sorensen, Kyrre E. Emblem, Pavlina Polaskova, Dominique Jennings, Heisoog Kim, Marek Ancukiewicz, Meiyun Wang, Patrick Y. Wen, Percy Ivy, Tracy T. Batchelor, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2012) 72 (2): 402–407.
https://doi.org/10.1158/0008-5472.CAN-11-2464
Published: 16 January 2012
View article titled, Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
Open the PDF for Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion in another window
Includes: Supplementary data
Journal Articles

Abstract LB-213: Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer

Dan G. Duda, Christopher G. Willett, Marek Ancukiewicz, Emmanuelle di Tomaso, Mira Shah, Brian G. Czito, Rex Bentley, Martin Poleski, Gregory Y. Lauwers, Madeline Carroll, Douglas Tyler, Christopher Mantyh, Paul Shellito, Jeffrey W. Clark, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): LB-213.
https://doi.org/10.1158/1538-7445.AM10-LB-213
Published: 15 April 2010
View article titled, Abstract LB-213: Plasma soluble VEGFR1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
Journal Articles

Abstract LB-76: A study of neoadjuvant bevacizumab with standard chemoradiation versus chemoradiation alone in locally advanced rectal cancer

Christopher G. Willett, Dan G. Duda, Marek Ancukiewicz, Mira Shah, Brian Czito, Rex Bentley, Martin Poleski, Hiroshi Fujita, Gregory Y. Lauwers, Madeline Carroll, Douglas Tyler, Christopher Mantyh, Paul Shellito, Daniel C. Chung, Jeffrey W. Clark, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): LB-76.
https://doi.org/10.1158/1538-7445.AM10-LB-76
Published: 15 April 2010
View article titled, Abstract LB-76: A study of neoadjuvant bevacizumab with standard chemoradiation versus chemoradiation alone in locally advanced rectal cancer
Journal Articles

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

Lei Xu, Dan G. Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Daniel C. Chung, Gregory Y. Lauwers, Rekha Samuel, Paul Shellito, Brian G. Czito, Pei-Chun Lin, Martin Poleski, Rex Bentley, Jeffrey W. Clark, Christopher G. Willett, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2009) 69 (20): 7905–7910.
https://doi.org/10.1158/0008-5472.CAN-09-2099
Published: 14 October 2009
View article titled, Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer
Open the PDF for Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer in another window
Journal Articles

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

A. Gregory Sorensen, Tracy T. Batchelor, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Y. Wen, Johanna Lahdenranta, Marek Ancukiewicz, Emmanuelle di Tomaso, Dan G. Duda, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2009) 69 (13): 5296–5300.
https://doi.org/10.1158/0008-5472.CAN-09-0814
Published: 01 July 2009
View article titled, A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
Open the PDF for A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients in another window
Includes: Multimedia, Supplementary data
Journal Articles

Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study

A. Gregory Sorensen, Tracy Batchelor, Marek Ancukiewicz, Wei-Ting Zhang, Poe-Jou Chen, Priscilla Yeo, Meiyun Wang, Dominique Jennings, Patrick Wen, Johanna Lahdenranta, Emmanuelle di Tomaso, Dan Duda, Rakesh Jain
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): LB-94.
Published: 01 May 2009
View article titled, Abstract #LB-94: A \#8220;vascular normalization index\#8221; as a mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients: Insights from a Phase II study
Journal Articles

Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer

Christopher G Willett, Lei Xu, Dan G Duda, Emmanuelle di Tomaso, Yves Boucher, Johanna Lahdenranta, Marek Ancukiewicz, Johanna Bendell, Brian Czito, Lawrence Blaszkowsky, Jeffrey Clark, Rakesh K Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-304.
https://doi.org/10.1158/1538-7445.AM2008-LB-304
Published: 15 May 2008
View article titled, Abstract LB-304: Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer
Journal Articles

Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Tracy T Batchelor, Gregory Sorensen, Emmanuelle di Tomaso, Dan G Duda, Wei-Ting Zhang, Marek Ancukiewicz, Johanna Lahdenranta, David Louis, Scott Plotkin, Percy Ivy, Jay S Loeffler, Patrick Wen, Rakesh K Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-247.
https://doi.org/10.1158/1538-7445.AM2008-LB-247
Published: 15 May 2008
View article titled, Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Journal Articles

Efficacy, safety, and changes in blood markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a multidisciplinary Phase II study

Andrew Zhu, Dushyant Sahani, Emmanuelle di Tomaso, Vivek Sindhwani, Marek Ancukiewicz, Sam Yoon, Lawrence Blaszkowsky, David Ryan, Dan Duda, Jeffrey Clark, Rakesh Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-139.
Published: 01 May 2008
View article titled, Efficacy, safety, and changes in blood markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a multidisciplinary Phase II study
Journal Articles

A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Tracy Batchelor, Gregory Sorensen, Emmanuelle di Tomaso, Dan Duda, Wei-Ting Zhang, Marek Ancukiewicz, Johanna Lahdenranta, David Louis, Scott Plotkin, Percy Ivy, Jay Loeffler, Patrick Wen, Rakesh Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-247.
Published: 01 May 2008
View article titled, A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
Journal Articles

Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer

Christopher Willett, Lei Xu, Dan Duda, Emmanuelle di Tomaso, Yves Boucher, Johanna Lahdenranta, Marek Ancukiewicz, Johanna Bendell, Brian Czito, Lawrence Blaszkowsky, Jeffrey Clark, Rakesh Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): LB-304.
Published: 01 May 2008
View article titled, Evaluation of the effects of anti-VEGF therapy in a multidisciplinary phase I/II study of neoadjuvant bevacizumab with chemoradiation therapy in rectal cancer
Journal Articles

A multidisciplinary phase II study of bevacizumab combined with oxaliplatin, gemcitabine in women with recurrent mullerian carcinoma

Neil Horowitz, Richard Penson, Yves Boucher, Emmanuelle di Tomaso, Alan Fishman, Marek Ancukiewicz, Carolyn Krasner, Suzanne Berlin, Maria Roche, Modjulie King, Anthony Luzzi, Julie Lee, Dan Duda, Rakesh Jain
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 4484.
Published: 01 May 2008
View article titled, A multidisciplinary phase II study of bevacizumab combined with oxaliplatin, gemcitabine in women with recurrent mullerian carcinoma
Journal Articles

Anti-VEGFR-3 Therapy and Lymph Node Metastasis

Timothy P. Padera, Marek Ancukiewicz, Tohru Hoshida, Dai Fukumura, Rakesh K. Jain
Journal: Cancer Research
Cancer Res (2007) 67 (10): 5055.
https://doi.org/10.1158/0008-5472.CAN-06-2935
Published: 17 May 2007
View article titled, Anti-VEGFR-3 Therapy and Lymph Node Metastasis
Open the PDF for Anti-VEGFR-3 Therapy and Lymph Node Metastasis in another window
Journal Articles

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients

Tracy Batchelor, Dan Duda, Emmanuelle di Tomaso, Kevin Kozak, Wei-Ting Zhang, Marek Ancukiewicz, Jay Loeffler, Patrick Wen, Gregory Sorensen, Rakesh Jain
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 2118.
Published: 01 May 2007
View article titled, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients